CD16 / Fcgamma Receptor III (CB16), 0.2mg/mL [26628-22-8]

Biotium

CD16 / Fcgamma Receptor III (CB16), 0.2mg/mL

9

Research Use Only

Monoclonal

CB16

0.2 mg/ml

FCGR3A

Fc fragment of IgG receptor IIIa

CD16; CD16A; CD16a antigen; Fc fragment of IgG, low affinity III, receptor for (CD16); Fc fragment of IgG, low affinity IIIa, receptor (CD16a); Fc gamma receptor III-A; FCG3; Fc-gamma receptor III-2 (CD 16); Fc-gamma receptor IIIb (CD16); Fc-gamma RIII-alpha; FcgammaRIIIA; FCGR3; FCGRIII; FCR-10; FCRIII; FCRIIIA; IGFR3; igG Fc receptor III-2; IMD20; immunoglobulin G Fc receptor III; low affinity immunoglobulin gamma Fc region receptor III-A; low affinity immunoglobulin gamma receptor III-a Fc fragment; neutrophil-specific antigen NA

Mouse

IgM

Low affinity immunoglobulin gamma Fc region receptor III-A

This antibody recognizes CD16 (FcgammaRIII), the low-affinity receptor for IgG with an apparent molecular weight of 50-80 kDa. CD16 is represented by two similar genes, CD16A (FcgammaRIIIA), which exists as a hetero-oligomeric polypeptide-anchored form in macrophages and NK cells and CD16B (FcgammaRIIIB), which exist as a monomeric GPI-anchored form in neutrophils. Furthermore, there are two known polymorphisms of CD16B, NA-1 and NA-2. Individuals homozygous for NA-2 show a lower phagocytic capacity compared with NA-1. CD16 binds IgG in the form of immune complexes and shows preferential binding of IgG1 and IgG3 isotypes and minimal binding of IgG2 and IgG4. Upon IgG binding, both CD16 isoforms initiate signal transduction cascades that lead to a variety of responses including antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, degranulation and proliferation. This antibody is available purified with BSA/azide at 200 ug/mL, or BSA/azide-free at 1 mg/mL.

Animal

Bovine, Human, Mouse

2°C to 8°C

12352203